Choomit

Choomit is an innovative biotechnology company dedicated to transforming the administration of biologic therapies from injections to oral dosage forms. Utilizing its proprietary Choom platform, the company addresses the long-standing challenge of transporting large, fragile molecules across the gastrointestinal tract into the bloodstream. The technology is designed to protect therapeutic payloads from degradation while enhancing their permeability through the intestinal wall. Choomit's current development focus includes oral versions of insulin, GLP-1 receptor agonists, and TNF-alpha inhibitors for metabolic and inflammatory conditions. By improving the ease of administration, the company seeks to significantly enhance patient adherence and quality of life for those with chronic diseases.